stockrow
Saturday 7 November 2026
Export NERV’s income statement to Excel — free account
Minerva Neurosciences, Inc
NERV Healthcare Biotechnology
- EPS
- +183.7%
- Free cash flow
- −553.5%
Quarter to June 2026, against a year earlier
2.42
0.12
+5.22%
Follow NERV
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | 41 | — | — | — | — | — | — | — | 19 | 19 | 19 | 0.0% | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 100.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | (31) | (41) | (50) | (74) | 2 | (52) | (32) | (30) | 1 | (293) | (394) | +28.3% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 4.71 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | (31) | (32) | (50) | (72) | 2 | (50) | (32) | (30) | 1 | (293) | (394) | +28.3% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 8.07 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (7.92) | (6.64) | (10.32) | (14.80) | 0.40 | (9.36) | (6.01) | (4.61) | 0.19 | (34.67) | (28.37) | +17.8% | ||||||
| Cash flow | (6.52) | 0.65 | (8.65) | (8.91) | (6.63) | (4.61) | (4.61) | (2.27) | (2.58) | (1.60) | (0.56) | (14.5%) | ||||||
| Capex | 0.00 | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | (6.52) | 0.64 | (8.65) | (8.91) | (6.63) | (4.61) | (4.62) | (2.27) | (2.58) | (1.60) | (0.56) | (14.5%) | ||||||
| Book value | 26.90 | 27.75 | 18.61 | 5.70 | 10.32 | 1.49 | (3.75) | (4.37) | (3.39) | (16.63) | (4.58) | n/m | ||||||
| Shares, m | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 7 | 8 | 8 | 27 | +8.9% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | 29.25 | — | — | — | — | — | 0.00 | — | |||||
| P/S | — | — | — | — | 0.00 | — | — | — | — | — | 0.00 | — | ||||||
| P/B | — | — | — | — | 1.81 | — | — | — | — | — | 0.00 | — | ||||||
| EV/Sales | — | — | — | — | 0.00 | — | — | — | — | — | 0.00 | — | ||||||
| EV/FCF | — | — | — | — | (2.16) | — | — | — | — | — | (1.55) | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (26) | 3 | (42) | (43) | (34) | (25) | (25) | (15) | (20) | (14) | (26) | (6.9%) | |||||
| Capex | — | 0 | — | — | — | — | 0 | — | — | — | 0 | (20.8%) | ||||||
| Free cash flow | (26) | 3 | (42) | (43) | (34) | (25) | (25) | (15) | (20) | (14) | (26) | (6.9%) | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 74 | 123 | 86 | 41 | 24 | 59 | 39 | 39 | 19 | 81 | 76 | +1.0% | |||||
| Net debt | (79) | (128) | (88) | (46) | (25) | (61) | (36) | (41) | (21) | (82) | (75) | +0.4% | ||||||
| Shareholders’ equity | 106 | 132 | 90 | 28 | 53 | 8 | (20) | (28) | (26) | (141) | (213) | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (28.81) | (19.91) | (31.08) | (66.64) | 2.87 | (74.07) | (48.57) | (53.59) | 3.06 | (434.34) | (629.71) | (405.5) pt | |||||
| ROIC | (70.51) | (766.68) | (1,491.63) | 0.00 | 4.24 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | +70.5 pt | ||||||
| ROE | (38.49) | (26.54) | (45.23) | (122.30) | 4.83 | (164.60) | 532.98 | 123.78 | (5.31) | 352.58 | 322.05 | +391.1 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 11 | 12 | 13 | 13 | 11 | 9 | 9 | 9 | 8 | 7 | — | (4.9%) | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 3.74 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2020 · latest quarter Jun 2020 · fundamentals updated 26 Oct 2026
Minerva Neurosciences, Inc vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| FHTX Foghorn Therapeutics Inc. | $113.1M | — (loss-making) | — (loss-making) | +112.68% (above 0%: growing) | n/m | +14.88% (above 0%: growing) | 100.00% | (54.78%) | Compare |
| ENGN enGene Therapeutics Inc | $112.6M | — (loss-making) | — | — | n/m | +28.07% (above 0%: growing) | — | 0.00% | Compare |
| NKTX Nkarta, Inc. | $112.5M | — (loss-making) | — | — | n/m | −29.19% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| CDXS Codexis, Inc. | $111.7M | — (loss-making) | — (loss-making) | −2.69% (below 0%: shrinking) | n/m | +48.60% (above 0%: growing) | 76.45% | (75.29%) | Compare |
| ARMP Armata Pharmaceuticals, Inc. | $111.5M | — (loss-making) | — (loss-making) | +15.72% (above 0%: growing) | n/m | −17.98% (below 0%: shrinking) | 100.00% | (410.84%) | Compare |
| HUMA Humacyte, Inc. | $109.9M | — (loss-making) | — (loss-making) | +34.88% (above 0%: growing) | n/m | +17.85% (above 0%: growing) | (203.20%) | (6,649.26%) | Compare |
| NERV Minerva Neurosciences, Inc | $109.8M | — (loss-making) | — (loss-making) | — | n/m | −553.48% (below 0%: shrinking) | 0.00% | 0.00% | |
| OTLK Outlook Therapeutics, Inc. | $106.9M | — (loss-making) | — (loss-making) | −99.42% (below 0%: shrinking) | n/m | −76.54% (below 0%: shrinking) | (95.40%) | (124,255.17%) | Compare |
| VYGR Voyager Therapeutics, Inc. | $106.0M | — (loss-making) | — (loss-making) | −69.97% (below 0%: shrinking) | n/m | +37.08% (above 0%: growing) | 100.00% | (658.25%) | Compare |
| Median of peers | $111.6M | — | — | +6.52% | — | +16.37% | 76.45% | (243.06%) |
Pay and ownership Proxy statement filed 23 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 9.35m | 9.86m | 252.83 |
| 2024 | 1.21m | 1.26m | 139.62 |
| 2023 | 1.84m | 2.13m | 386.79 |
Ownership
Directors and executive officers, together
1.70%
Funds affiliated with Federated Hermes, Inc.
19.10%
Entities affiliated with Vivo Capital
9.99%
Entities affiliated with Janus Henderson Investors
9.99%
Atlas Private Holdings (Cayman) Ltd.
9.99%
Entities affiliated with Logos Global Management LP
9.99%
Entities affiliated with Farallon Capital Management, L.L.C.
9.99%
Entities affiliated with Seven Fleet Partners LP
8.30%
Foresite Capital Fund VI LP
6.40%
Adage Capital Partners LP
6.30%
Trails Edge Biotechnology Master Fund, LP
6.30%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement